Loading...
•
Dec 31, 2025
•/
Stevanato Group Q4 2025 Earnings Report
Stevanato Group reported moderate revenue growth and margin expansion in Q4 2025, supported by strong demand for high-value solutions.
Key Takeaways
Stevanato Group delivered solid fourth-quarter performance with revenue growth driven by its Biopharmaceutical and Diagnostic Solutions segment and strong demand for high-value solutions. Profitability improved with higher gross margins and expanded adjusted EBITDA margins despite a decline in the Engineering segment.
Revenue increased 5% year-over-year to €346.5 million in Q4 2025.
High-value solutions revenue grew 31% year-over-year, reaching €171.4 million and representing 49% of total revenue.
Gross margin expanded to 30.9%, improving by 120 basis points year-over-year.
Engineering segment revenue declined 23% year-over-year, partially offsetting strength in the core BDS segment.
Revenue by Segment
Forward Guidance
For fiscal 2026, Stevanato Group expects continued growth supported by strong demand for biologics and improved utilization of newly built facilities.
Positive Outlook
- Revenue expected between €1.26 billion and €1.29 billion.
- Adjusted EBITDA projected between €331.8 million and €346.9 million.
- Adjusted diluted EPS expected between €0.59 and €0.63.
- Increasing demand from biologics and GLP-1 drug markets.
- Improved utilization and operating leverage from new manufacturing plants.
Challenges Ahead
- Foreign currency fluctuations may continue to impact reported results.
- Engineering segment remains volatile with lower project volumes.
- Tariffs could create margin pressure.
- New facility start-up costs will continue to affect profitability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...